AI English summary of an SEC filing — figures as filed
Verisk Analytics VRSKVerisk said revenue for Q4 2024 rose 8.6% to $736 million, and full-year revenue rose 7.5% to $2,882 million. The company said adjusted EBITDA for Q4 rose 9.9% to $398 million, and full-year adjusted EBITDA rose 9.9% to $1,576 million.
Key points
AI summaryVerisk said revenue for Q4 2024 rose 8.6% to $736 million, and full-year revenue rose 7.5% to $2,882 million. The company said adjusted EBITDA for Q4 rose 9.9% to $398 million, and full-year adjusted EBITDA rose 9.9% to $1,576 million.
The company said income from continuing operations for 2024 rose to $951 million, up 23.7%. It cited revenue growth and cost discipline, a net gain of $100.6 million from the settlement of retained interests tied to the prior sale of its healthcare business and specialized markets business, and a lower effective tax rate as factors. It said the prior year included a litigation reserve expense of $38.2 million related to its former Financial Services segment.
The company said full-year 2024 net cash provided by operating activities was $1,144 million and free cash flow was $920 million, up 7.9% and 10.8%, respectively. In Q4 2024, it entered into and fully funded an accelerated share repurchase program of $300 million. Its board approved a cash dividend of $0.45 per share payable on March 31, 2025.
The company provided its outlook for fiscal 2025, with revenue of $3,030 million to $3,080 million, adjusted EBITDA of $1,670 million to $1,720 million, and diluted adjusted EPS of $6.80 to $7.10. It said the outlook reflects the impact of the AER divestiture and current foreign exchange rates, current interest rates and existing tax rates.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
2024 Q4 and Full-Year Revenue and Adjusted EBITDA
Verisk said revenue for Q4 2024 rose 8.6% to $736 million, and full-year revenue rose 7.5% to $2,882 million. The company said adjusted EBITDA for Q4 rose 9.9% to $398 million, and full-year adjusted EBITDA rose 9.9% to $1,576 million.
Source · Based on the filing body and exhibits
Full-Year Income from Continuing Operations and One-Time Items
The company said income from continuing operations for 2024 rose to $951 million, up 23.7%. It cited revenue growth and cost discipline, a net gain of $100.6 million from the settlement of retained interests tied to the prior sale of its healthcare business and specialized markets business, and a lower effective tax rate as factors. It said the prior year included a litigation reserve expense of $38.2 million related to its former Financial Services segment.
Source · Based on the filing body and exhibits
Cash Flow and Shareholder Returns
The company said full-year 2024 net cash provided by operating activities was $1,144 million and free cash flow was $920 million, up 7.9% and 10.8%, respectively. In Q4 2024, it entered into and fully funded an accelerated share repurchase program of $300 million. Its board approved a cash dividend of $0.45 per share payable on March 31, 2025.
Source · Based on the filing body and exhibits
Fiscal 2025 Outlook (Guidance)
The company provided its outlook for fiscal 2025, with revenue of $3,030 million to $3,080 million, adjusted EBITDA of $1,670 million to $1,720 million, and diluted adjusted EPS of $6.80 to $7.10. It said the outlook reflects the impact of the AER divestiture and current foreign exchange rates, current interest rates and existing tax rates.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…